The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
After a steep decline in market value, QuidelOrtho is planning to sell its diagnostic testing unit for about $1.5 billion to private equity firms, according to a Financial Times report. The move comes as part of a strategic review following a 90% plunge in the company's shares since the approval of its rapid antigen tests for Covid-19.
Sign in to access this content
Sign InThe potential sale reflects a broader restructuring in the diagnostics industry as demand for Covid-19 tests wanes, pushing companies to refocus on traditional product lines. QuidelOrtho has not commented on the report, but sources indicate the talks are still in early stages.
Investors are watching for further details on the deal, which could provide much-needed liquidity for the company. The market will also be looking for signs of operational turnaround after the divestiture of its pandemic-era assets.